Kinetics and dosimetry of MAb-170: Evaluation of possibilities for intraperitoneal radioimmunotherapy;Biokinetik und dosimetrie mit dem monokionalen antikörper MAb-170: Evaluation der möglichkeit einer intraperitonealen radioimmuntherapie

NuklearMedizin

Volumn 40, Issue 6, 2001, Pages 207-214

  Alexander, Ch ^a   Hollander M ^a   Schmidt, W ^a   Kirsch, C M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Dosimetry; Monoclonal antibodies; Ovarian cancer; Peritoneal carcinosis; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 170 RE 186; MONOCLONAL ANTIBODY 170 TC 99M; RHENIUM 186; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CASE REPORT; DOSIMETRY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; RADIOIMMUNOTHERAPY; SPLEEN; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

EID: 0035664258     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625283     Document Type: Article

References (17)

1. MAb-170 for immunoscintigraphic detection of ovarian tumors
2. 177Lu-CC49: A phase I/II study
3. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors
4. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies
5. Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: Biological basis, present status and future perspectives
6. Pharmacokinetics and normal organ dosimetry following intraperitoneal Rhenium-186-labeled monoclonal antibody
7. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration
8. Biodistribution of Indium-111-labelled OC125 monoclonal antibody intraperitoneally injected into patients operated for ovarian carcinomas
9. Treatment of metastatic breast and prostate cancer with In-111/Y-90 MAb170: Pharmacokinetic and therapy dosimetry
10. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody
11. Prospects of radioimmunotherapy in epithelial ovarian cancer: Results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies
12. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma
13. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer
14. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49
15. Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer
16. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity
17. Wissenschaftliche Tabellen Geigy, Teilband Somatometrie und Biochemie, 8